- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Pembrolizumab (scchn) – July 2018
Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
Last updated
9 November 2018